Method for increasing bioavailability of oral pharmaceutical compositions

• US 6,028,054 A
• Filed: 05/06/1998
• Issued: 02/22/2000
• Est. Priority Date: 02/02/1994
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Wu, Chi Yuan, Benet, Leslie Z.
• Primary Examiner(s): Russel, Jeffrey E.
• Application Number:
  US09/073,704
• Time in Patent Office: 657 Days
• Field of Search: 424/450, 424/452, 424/465, 514/9, 514/11, 514/506, 514/557, 514/579, 514/675, 514/693, 514/764, 514/772, 514/784, 514/788, 514/946
• US Class Current: 514/20.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/49 Cinchonan derivatives, e.g. quinine
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12Q 1/26 involving oxidoreductase
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

Claims

1. A method of formulating an oral pharmaceutical composition, which method comprises:

admixing a pharmaceutical compound, a pharmaceutical carrier, and a bioenhancer comprising an inhibitor of P-glycoprotein-mediated membrane transport or an inhibitor of a cytochrome P450 3A enzyme in normal gut tissue, said bioenhancer being active only in the gut when administered orally and being present in sufficient amount to provide bioavailability of said pharmaceutical compound in the presence of said bioenhancer greater than the bioavailability of said pharmaceutical compound in the absence of said bioenhancer when said pharmaceutical composition is administered orally to a mammal, and further wherein whether a bioenhancer is active only in the gut is determined by measuring change in bioavailability of said pharmaceutical compound when orally coadministered to said mammal with said bioenhancer, measuring change in integrated systemic concentration of said pharmaceutical compound when said pharmaceutical compound is intravenously administered and said bioenhancer is orally coadministered, and determining that said change in said bioavailability when said pharmaceutical compound is orally administered is a statistically significant increase and said change in said integrated systemic concentration when said pharmaceutical compound is intravenously administered is not statistically significant.

2. The method of claim 1, wherein said bioenhancer comprises an inhibitor of a cytochrome P450 3A enzyme and said inhibitor is a hydrophobic molecule.

3. The method of claim 1, wherein said bioenhancer comprises an inhibitor of a cytochrome P450 3A enzyme and said inhibitor is present in an amount sufficient to provide a lumen concentration equal to or greater than a concentration of said bioenhancer that reduces conversion of cyclosporine to hydroxylated products by 10%, compared to controls, in an assay system containing 100 μ

g human liver or enterocyte microsomes, 25 μ

M cyclosporine, and an NADPH regenerating system in 100 μ

l of 0.1 M sodium phosphate buffer, pH 7.4.

4. The method of claim 1, wherein said bioenhancer comprises an inhibitor of P-glycoprotein-mediated membrane transport and said inhibitor is a hydrophobic molecule comprising two co-planar aromatic rings, a positively charged nitrogen group, or a carbonyl group.

5. The method of claim 1, wherein said bioenhancer comprises an inhibitor of P-glycoprotein-mediated membrane transport and said inhibitor is present in the gut of said mammal at a concentration equal to or greater than a concentration that reduces transport of Rh 123 by P-glycoprotein in brush border membrane vesicles or P-gp-containing cells by 10%.

6. The method of claim 1, wherein said amount of said bioenhancer is sufficient to produce a concentration of said bioenhancer in the lumen of the gut of said mammal of at least 0.1 times said K_j or apparent K_i of said bioenhancer.

7. The method of claim 1, wherein said bioenhancer comprises an inhibitor of a cytochrome P450 3A enzyme and a separate inhibitor of P-glycoprotein-mediated membrane transport.

8. The method of claim 1, wherein said bioenhancer comprises a single compound that inhibits both a cytochrome P450 3A enzyme and P-glycoprotein-mediated membrane transport.

9. The method of claim 1, wherein said bioenhancer is present as a counter ion of said pharmaceutical compound.

10. The method of claim 1, wherein said bioenhancer is covalently bound to said pharmaceutical compound.

11. The method of claim 1, wherein said pharmaceutical compound comprises an acetanilide, aminoacridine, aminoquinoline, anilide, anthracycline antibiotic, antiestrogen, benzazepine, benzhydryl compound, benzodiazapine, benzofuran, cannabinoid, cephalosporine, colchicine, cyclic peptide, dibenzazepine, digitalis glycoside, dihydropyridine, epipodophyllotoxin, ergot alkaloid, imidazole, isoquinoline, macrolide, naphthalene, nitrogen mustard, opioid, oxazine, oxazole, phenothiazine, phenylalkylamine, phenylpiperidine, piperazine, piperidine, polycyclic aromatic hydrocarbon, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, quinazoline, quinoline, quinone, rauwolfia alkaloid, retinoid, salicylate, steroid, stilbene, sulfone, sulfonylurea, taxol, triazole, tropane, or vinca alkaloid.

12. A pharmaceutical composition produced by the process of claim 1.

17. The method of claim 1, wherein said change in said bioavailability when said pharmaceutical compound is orally coadministered with said bioenhancer has a statistical p-value of no more than 0.006.

18. The method of claim 1, wherein said change in said integrated systemic concentration when said pharmaceutical compound is intravenously administered and said bioenhancer is orally coadministered has a statistical p-value of no less than 0.10.

19. The method of claim 1, wherein said change in said bioavailability when said pharmaceutical compound is orally coadministered with said bioenhancer has a statistical p-value of no more than 0.006 and said change in said integrated systemic concentration when said pharmaceutical compound is intravenously administered and said bioenhancer is orally coadministered has a statistical p-value of no less than 0.10.

20. The method of claim 1, wherein bioavailability in the presence of said inhibitor is greater than bioavailability of said compound in its absence by at least 10% of the difference between bioavailability in its absence and complete oral bioavailability.

21. The method of claim 1, wherein said bioenhancer reduces inter-individual variability of said bioavailability of said pharmaceutical compound.

22. The method of claim 1, wherein said bioenhancer reduces intra-individual variability of said bioavailability of said pharmaceutical compound.

13. A method of increasing bioavailability of the active compound in a first oral pharmaceutical composition, which method comprises:

reformulating said first composition to provide a reformulated composition by admixing said active compound with a bioenhancer comprising an inhibitor of cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport in normal gut tissue, said bioenhancer being active only in the gut when administered orally and being present in sufficient amount to provide bioavailability of said active compound when administered in said reformulated composition greater than said bioavailability of said active compound when administered in said first pharmaceutical composition, and further wherein whether a bioenhancer is active only in the gut is determined by measuring change in bioavailability of said active compound when orally coadministered to said mammal with said bioenhancer, measuring change in integrated systemic concentration of said active compound when said active compound is intravenously administered and said bioenhancer is orally coadministered, and determining that said change in said bioavailability when said active compound is orally administered is a statistically significant increase and said change in said integrated systemic concentration when said active compound is intravenously administered is not statistically significant.

14. The method of claim 13, wherein said reformulated composition comprises all components present in said first pharmaceutical composition plus said bioenhancer.

15. The method of claim 13, wherein said reformulated composition contains less than all components present in said first pharmaceutical composition plus said bioenhancer.

16. A reformulated pharmaceutical composition produced by the method of claim 13.

23. The method of claim 13, wherein said change in said bioavailability when said active compound is orally coadministered with said bioenhancer has a statistical p-value of no more than 0.006.

24. The method of claim 13, wherein said change in said integrated systemic concentration when said active compound is intravenously administered and said bioenhancer is orally coadministered has a statistical p-value of no less than 0.10.

25. The method of claim 13, wherein said change in said bioavailability when said active compound is orally coadministered with said bioenhancer has a statistical p-value of no more than 0.006 and said change in said integrated systemic concentration when said active compound is intravenously administered and said bioenhancer is orally coadministered has a statistical p-value of no less than 0.10.

26. The method of claim 13, wherein said active compound comprises an acetanilide, aminoacridine, aminoquinoline, anilide, anthracycline antibiotic, antiestrogen, benzazepine, benzhydryl compound, benzodiazapine, benzofuran, cannabinoid, cephalosporine, colchicine, cyclic peptide, dibenzazepine, digitalis glycoside, dihydropyridine, epipodophyllotoxin, ergot alkaloid, imidazole, isoquinoline, macrolide, naphthalene, nitrogen mustard, opioid, oxazine, oxazole, phenothiazine, phenylalkylamine, phenylpiperidine, piperazine, piperidine, polycyclic aromatic hydrocarbon, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, quinazoline, quinoline, quinone, rauwolfia alkaloid, retinoid, salicylate, steroid, stilbene, sulfone, sulfonylurea, taxol, triazole, tropane, or vinca alkaloid.